TITLE PAGE

1

2

3 Title: COVID MED – An Early Pandemic Trial of Losartan for Hospitalized 4 **COVID-19 Patients** 5 **Authors/Affiliations:** Daniel Freilich, MD, Bassett Medical Center (Cooperstown, NY, USA), 6 daniel.freilich@bassett.org 7 Jennifer Victory, RN, BS, Bassett Research Institute (Cooperstown, NY, 8 USA), iennifer.victory@bassett.org 9 Paul Jenkins, PhD, Bassett Research Institute (Cooperstown, NY, USA), 10 paul.jenkins@bassett.org 11 James Wheeler, MD, Goshen Health (Goshen. IN. USA). 12 jwheeler@goshenhealth.com 13 G. Matthew Vail, MD, Reid Health (Richmond, IN, USA), matthew.vail@reidhealth.org 14 15 Erik Riesenfeld, MD, Bassett Medical Center (Cooperstown, NY, USA), 16 erik.riesenfeld@bassett.org 17 Peggy Cross, Bassett Research Institute (Cooperstown, NY, USA), 18 peggy.cross@bassett.org 19 Catherine Gilmore, RN, Bassett Research Institute (Cooperstown, NY, 20 USA), catherine.gilmore@bassett.org 21 Melissa Huckabone, RN, Bassett Research Institute (Cooperstown, NY, 22 USA), melissa.huckabone@bassett.org 23 Anna Schworm, RN, Bassett Research Institute (Cooperstown, NY, 24 USA), annaschworm@gmail.com Umesha Boregowda, MD, Bassett Medical Center (Cooperstown, NY, 25 USA), umesha.boregowda@bassett.org 26 27 Farah Deshmukh, MD, Bassett Medical Center (Cooperstown, NY, 28 USA), farah.deshmukh@gmail.com 29 Yuri Choi, MD, Bassett Medical Center (Cooperstown, NY, USA), 30 yuri.choi@bassett.org 31 Azkia Khan, MD, Bassett Medical Center (Cooperstown, NY, USA), 32 azkia.kahn@bassett.org Anne Gadomski, MD, MPH, Bassett Research Institute (Cooperstown, 33 34 NY, USA), anne.gadomski@bassett.org 35 **Corresponding Author:** Daniel Freilich, MD, Bassett Medical Center, 1 Atwell Rd, Cooperstown, 36 NY 13326 (USA). daniel.freilich@bassett.org

37 38 39	Authors' contributions:	DF conceived of the study. DF, JV, and AG initiated the study design and DF, JV, JW, GMV, ER, PC, CG, MH, AS, UB, FD, YC, AK, and AG helped with implementation.
40		FD, YC, and AK are grant holders.
41 42		PJ provided statistical expertise in clinical trial design and in conducting the primary statistical analysis.
43 44		All authors contributed to refinement of the study protocol and approved the final manuscript.
45	DOI Statement:	None of the authors have any competing/conflicting interests to declare
46	Authorship Role:	All authors collaborated in the writing/editing of the manuscript
47	Article Type:	Original article – RCT
48	Running Head:	Losartan for COVID-19
49		

ABSTRACT

51 Background

50

- 52 ACEi/ARB medications have been hypothesized to have potential benefit in COVID-19. Despite concern
- for increased ACE-2 expression in some animal models, preclinical and observational-retrospective and
- uncontrolled trials suggested possible benefit. Two RCTs of the ARB losartan from University of
- Minnesota showed no benefit yet safety signals for losartan in outpatient and hospitalized COVID-19
- 56 patients. COVID MED, started early in the pandemic, also assessed losartan in a RCT in hospitalized
- patients with COVID-19.
- 58 Methods
- 59 COVID MED was quadruple-blinded, placebo-controlled, multicenter randomized clinical trial (RCT).
- 60 Hospitalized COVID-19 patients were randomized to receive standard care and hydroxychloroquine,
- 61 lopinavir/ritonavir, losartan, or placebo. Hydroxychloroquine and lopinavir/ritonavir arms were
- 62 discontinued after RCTs showed no benefit. We report data from the losartan arm compared to combined
- 63 (lopinavir-ritonavir and placebo) and prespecified placebo-only controls. The primary endpoint was the
- NCOSS slope of change. Slow enrollment prompted early stopping.
- 66 Results

65

- 67 Of 432 screened patients, 14 were enrolled (3.5%), 9 received losartan and 5 combined control
- 68 (lopinavir/ritonavir [N=2], placebo [N=3]); 1 hydroxychloroquine arm patient was excluded. Most
- 69 baseline parameters were balanced. Treatment with losartan was not associated with a difference in
- NCOSS slope of change in comparison with combined control (p=0.4) or placebo-only control (p=0.05)
- 71 (trend favoring placebo). 60-day mortality and overall AE and SAE rates were numerically but not
- significantly higher with losartan.
- 73 Conclusions
- 74 In this small blinded RCT in hospitalized COVID-19 patients, losartan did not improve outcome vs.
- 75 control comparisons and was associated with adverse safety signals.
- 78 Keywords
- 79 Losartan, angiotensin converting enzyme inhibitor (ACEi), angiotensin II receptor blocker (ARB),
- 80 COVID-19, SARS-CoV-2, randomized clinical trial (RCT)

INTRODUCTION

Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) have been hypothesized to have benefit in COVID-19 secondary to inhibition of pneumocyte ACE-2 receptors resulting in decreased SARS-CoV-2 entry, as well as local vasodilation/vasoconstriction alteration and anti-inflammatory effects. Animal studies suggested potential for benefit. Safety concerns have included observations of increased ACE-2 receptor expression in some animal models and potential for medication class adverse events (e.g., acute kidney injury [AKI]). Retrospective and observational continuation-discontinuation trials [1-10], open-label interventional trials [11-15], and a meta-analysis [16] showed trends favoring benefit. Two blinded RCTs, however, showed no benefit yet adverse safety signals [17-18]. We initiated the COVID MED trial at the pandemic onset prior to publication of ACEi/ARB COVID-19 clinical trials, aiming to assess the ARB losartan (and hydroxychloroquine and lopinavir/ritonavir) in hospitalized COVID-19 patients.

MATERIALS AND METHODS

COVID MED (NCT04340557) was approved by the Institutional Review Boards of Bassett Medical Center (Cooperstown, NY [April 3, 2020] [#1581969]), Goshen Health (Goshen, IN) and Reid Health (Richmond, IN). Initiated at the pandemic onset, we could not project COVID-19 admission numbers, thus, an arbitrary N of 4,000 hospitalized patients with laboratory-confirmed SARS-CoV-2 (screening criteria) was selected with prespecification for sample size/power calculations and updating after interim analysis. Our primary objective was to assess whether treatment with hydroxychloroquine, lopinavir/ritonavir, or losartan, would result in more rapid improvement in the 7-point NIAID COVID-19 Ordinal Scale Score (NCOSS) in comparison with placebo. NCOSS is as follows: 1) Death; 2) Hospitalized, on mechanical ventilation or ECMO; 3) Hospitalized, on NIV/high flow oxygen; 4) Hospitalized, requiring oxygen; 5) Hospitalized, not requiring oxygen; 6) Not hospitalized, with limitations; 7) Not hospitalized, without limitations. Enrolled patients were followed for up to 60 days.

Target recruitment was maximized by daily assessment of positive SARS-CoV-2 swab tests from Bassett's laboratory in hospitalized patients with review of inclusion/exclusion criteria for all such patients by the study's enrollment nurse and offering enrollment to all interested in participating after a comprehensive informed consent process (see Supplementary material for Informed Consent Form [ICF]). Post-consent, patients were randomly assigned by an unblinded enrollment research nurse in a 2:2:2:1 ratio in blocks to one of four groups using a computer-generated randomization schedule provided by the study's statistician (without stratification): hydroxychloroquine, lopinavir/ritonavir, losartan, or

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133134

135

136

137

138

139

140

141

142

143

144

145

146

placebo; this ratio was selected because early in the pandemic patients declined participation in trials with low likelihood of receiving 'active' drug. Allocation concealment was ensured by having only the enrollment research nurse be unblinded and with maintaining confidentiality of the allocation. All groups received standard care, which transformed over time. Hydroxychloroquine and lopinavir/ritonavir enrollment were halted after other RCTs showed no benefit [19-20]; a 2:1 ratio computer-generated randomization schedule for losartan and placebo was used thereafter. Herein, we focus on the trial design and results for losartan vs. combined control groups (we included 2 lopinavir/ritonavir patients as other RCTs showed no benefit or safety concerns [20]. We also report ITT data for the comparison of the losartan and placebo-only group, per our prespecified statistical analysis plan (SAP). Low enrollment led to study termination (July 2021). Inclusion criteria were (1) hospitalized; (2) >18 years-old; (3) laboratory-confirmed SARS-CoV-2 infection; (4) randomization within 72 hours of admission; and (5) able to provide consent. General exclusion criteria applicable to all groups included (1) ESRD; (2) severe hepatic insufficiency; (3) nausea/vomiting/aspiration risk precluding oral medications unless can be given by nasogastric tube; (4) use of another SARS-CoV-2 medication; (5) pregnancy/breast feeding; (6) no contraception; and (7) inability to obtain consent. Each treatment group had specific exclusions based on the medication's safety profile. Specific losartan group exclusion criteria included (1) ARB allergy/intolerance; (2) taking ACEi/ARB; (3) hypotension; (4) hyperkalemia; (4) severe renal dysfunction; (5) severe volume depletion/AKI: (6) ascites: (7) aortic/mitral stenosis: (8) renal artery stenosis: and (9) co-administration of CYP3A interacting drugs, Minor modifications were made during the study. There were no placebo group specific exclusion criteria. After hydroxychloroquine and lopinavir-ritonavir enrollment was stopped, inclusion/exclusion criteria were the same for the losartan and placebo groups. Study drug (losartan or TicTacs placebo [lopinavir-ritonavir in 2 patients]) was prepared by a pharmacist who inserted the 'pills' into blank capsules – enabling cost-effective quadruple-blinding (patient, clinical nurse/physician, study nurse, investigators); only the enrollment study nurse was unblinded but he/she had no other responsibilities after enrollment. Unblinding was not done. If crushed drug or drug in solution had to be administered (nasogastric/gastric tube), eye shields were used to maintain blinding. Dosing was initially twice daily in all groups to mask varying regimens (losartan group: losartan and placebo; placebo group: placebo and placebo; lopinavir/ritonavir group: lopinavir/ritonavir twice daily). The losartan dose was 25 mg; the lopinavir/ritonavir dose was 400/100 mg. After hydroxychloroquine and lopinavir/ritonavir groups enrollment ceased, losartan and placebo dosing were daily. Dosing duration target was 14 days (minimum 5 days) if tolerated (no clinically relevant related AEs/SAEs such as hypotension, hyperkalemia, or worsening renal function). Adherence to study dosing was monitored and

148

149

150

151152

153154

155

156157

158

159

160

161

162

163

164165

166

167

168

169

170

171

172

173

174

175

176

177

178

noted by the study's research nurse. Patients discharged early were administered a shorter 5-day course with a minimum of 1.5 days as an in-patient (3 doses) and 3.5 days as an out-patient (7 doses). With the initial study plan to recruit up to 4,000 subjects, the 2:2:2:1 assignment was predicted to result in 571 subjects in the placebo group and 1,143 subjects in each treatment group. An independent, conflictfree, and multidisciplinary Data Monitoring Committee (DMC) was convened at the study's outset and agreed to its processes and goals; unexpected SAE reports were shared with the DMC. Interim analysis was planned for each treatment group at an information fraction of 0.1, which would occur when a treatment group had slopes for 114 subjects, and the control group has slopes for 57. After hydroxychloroquine and lopinavir/ritonavir were dropped, we planned interim analysis and sample size optimization upon enrollment of 114 losartan and 57 placebo subjects. However, the study was stopped due to slow enrollment prior to the first planned DMC interim analysis. Protocol CRFs were used to collect standardized efficacy/safety data; telephone follow-up was used as much as possible after discharge to obtain planned efficacy/safety data but inability to meet participants due to COVID-19 safety restrictions precluded complete data collection. Additional blood tests for more extensive safety monitoring were completed for patients who consented. AEs were classified in accordance with NCICTC for Adverse Events, version 4.0 (standard grading procedures). COVID MED was carried out in accordance with principles of the Code of Ethics of the World Medical Association (Declaration of Helsinki) and GCP guidelines of the International Conference on Harmonization, with general principles of protection of humans participating in research. Data from CRFs and AE/SAE reports were entered into REDCap using secure login/password entry; data were deidentified in working documents which were available only to study investigators; all study identifying data will be destroyed/deleted upon publication to allow wider sharing if requested. Statistical Analysis As per our prespecified SAP, subjects had NCOSS values recorded for up to 11 timepoints (days 0, 1-7, 14, 30, and 60). These 11 X (time) Y (NCOSS) pairs were be used to calculate the slope of the change in NCOSS values over time for each subject. Only X-Y pairs up to and including the first attainment of NCOSS level 7 were included. These slopes of the change in NCOSS levels over time served as the primary endpoint for each subject. The study design was such that it constituted three unique trials, all of which utilized the same control (placebo) group. Means of the slopes for each of the three different treatments were compared separately to mean slope in the control group using Student's t-test. We report methods/results for comparison of the

179 losartan vs. placebo-only arms per the prespecified SAP, but also, because of our small N, post-hoc

comparison with combined controls (lopinavir/ritonavir and placebo).

Continuous and categorical secondary endpoints were compared using Student's t-test and Fisher's exact

test, respectively. Secondary analyses included but were not limited to hospital LOS, mechanical

ventilation duration, and 60-day mortality. Time to resolution of nasopharyngeal viral shedding (PCR)

was compared. For safety, the primary outcome was the intention-to-treat (ITT) 60-day overall SAE rate;

secondary measurements included overall AE rates, and AKI, hypotension, and hyperkalemia AE/SAE

rates. Adjusted and subgroups analyses were not done due to small sample size. For the primary outcome,

missing values were addressed with conventional last-observation-carried-forward (LOCF).

RESULTS

180

181

182

183

184

185

186

187

188

189

- 190 Screening/enrollment
- 191 Of 432 screened patients, 14 were enrolled (3.5%), 9 receiving losartan and 5 receiving control
- 192 (placebo=3, lopinavir/ritonavir=2); 1 hydroxychloroquine arm patient was not included herein. Reasons
- 193 for non-inclusion at Bassett: patient declined (12.0%), taking ACEi/ARB (26.9%), outside enrollment
- window (20.1%), hypotension (1.6%), hyperkalemia (2.1%), renal disease (4.2%), altered mental status
- precluding consent (11.6%), hospitalized for non-COVID-19 reasons (asymptomatic) (10.4%), and other
- 196 (11.1%).

- 198 Baseline parameters/demographics
- 199 Comparisons of losartan and combined control baseline data revealed balanced parameters other than
- comorbidities. Specifically, mean age was 63.7 vs. 61.8 years, and males accounted for 66.7% vs. 60%,
- respectively. 100% were Caucasian and 100% were ward patients in both groups. Mean NCOSS was 3.6
- vs. 4.0, (p=0.5), qSOFA 0.33 and 0.6 (p=0.4), and creatinine 0.7 vs. 0.9 (p=0.4), respectively. Chest x-ray
- opacities consistent with pneumonia were seen in 88.9 vs. 100% (p=0.9). PSI scores were similar 54.9
- and 59.3 (p=0.5). Mean BMI was 31.0 and 31.8 (p=0.4). The mean targeted comorbidities rate (per
- subject) was lower with losartan than combined control (1 vs. 2.6, p=0.02); a similar trend was seen for
- the Charlson Score (2.5 vs. 4.5, p=0.08). Treatment occurred at a median of 9.3 vs. 7.4 days after
- symptoms onset (p=0.3). Treatment duration mean was 9.6 vs. 13.3 days, respectively (p=0.3). 88.9 vs.
- 50% of patients received corticosteroids (p=0.5). Most patients were enrolled between the spring of 2020
- and the winter of 2021 (88.9 vs. 80%). Baseline comparisons for losartan vs. placebo-only control were
- similar (see Table 1).

213214

215

216

217

218

219

220221

222

223

224

225226

227

228

229

230

231

232

233

234235

236

237238

239

240

241242

243

244

Efficacy NCOSS data were recorded for 97% of losartan group timepoints (3% missingness), 94.5% of combined control (lopinavir/ritonavir and placebo) group timepoints, and 100% of placebo-only control group timepoints. The slopes of the change for NCOSS were 0.00365 for losartan (p=0.5), 0.02091 for combined control (p=0.07), and 0.05268 for placebo-only control (p=0.002). Comparisons of the slopes of the change for NCOSS, our primary outcome measurement, revealed: losartan vs. combined control (p=0.4), losartan vs. placebo-only control (p=0.05) (trend favoring placebo), combined control vs. placebo-only control (p=0.267) (see Figure 1). Mean NCOSS change at 60 days was numerically but not significantly lower with losartan (0.7) than combined control (1.8) (p=0.6). Mortality at 60 days (44.4 vs. 20%, p=0.9), mean LOS (16.4 vs. 7.0 days, p=0.2), and mean mechanical ventilation duration (8.5 vs. 0 days) were worse with losartan but also not significantly (see Table 2). Safety The primary safety outcome measurement, the overall SAE rate (per subject), was numerically higher with losartan vs. combined control (2.0 vs. 0.6%) and vs. the placebo-only control (2.0 vs. 0%). The overall AE rate (per subject) trend was similar, being higher with losartan than combined control (3.9 vs. 1.0%) and vs. placebo-only control (3.9 vs. 0%). AKI AE and SAE rates were similar, but hypotension and hyperkalemia, as well as respiratory failure AE and SAE rates, were numerically higher with losartan than combined control and placebo-only control. No safety comparison was statistically significantly different (see Table 3). Planned subgroups analysis and adjustment for baseline parameters was not done due to the small N of the enrolled population. **DISCUSSION** COVID MED, to our knowledge, the third blinded, placebo-controlled RCT assessing an ARB in COVID-19, did not find significant group differences in the NCOSS score for hospitalized patients treated with losartan vs. control. A statistically insignificant trend favoring control was found for our prespecified primary efficacy outcome measurement, the ITT comparison of the NCOSS slope of the change vs. placebo-only control (p=0.05). Our primary safety outcome measurement, overall SAE rate, was numerically but not statistically significantly higher with losartan. Secondary outcomes also

245 numerically favored placebo but no group comparisons were statistically significantly different -246 including mortality. 247 Although COVID MED was small and pilot-like in scope, its results are value-added in that they add 248 randomized, blinded, and placebo-controlled data to the limited ACEi/ARB literature in COVID-19. Our 249 results are similar to those found in two larger blinded RCTs [17-18]; these three RCTs do not support 250 empiric starting of ACEi/ARB, at least ARB, in COVID-19 outside of RCTs. Given the negative results 251 of these blinded studies, it is worth reviewing the evidence for ACEi/ARB in COVID-19. 252 Preclinical data 253 SARS-CoV and SARS-CoV-2 viruses enter cells by binding to cellular ACE2 receptors which are 254 expressed on lung type II pneumocytes, enterocytes, kidney, and vascular cells [21-26]. Animal viral 255 pneumonia models provided indirect support showing improved outcome with losartan, including 256 amelioration of lung injury, edema, and lung failure in a SARS-CoV infection model [26], and of lung 257 injury, edema, and leukocyte infiltration in an influenza A H5N1 mouse model [27]. 258 Some researchers raised concern early in the pandemic that ACEi/ARB might worsen COVID-19 259 outcome [28-29] because in some (not all) animal models, ACE2 expression may be upregulated by these 260 drugs potentially increasing virus cell injury [30-37]. Human studies do not show increased plasma ACE2 261 levels with ACEi/ARB [38-40]. ARB have been hypothesized to stabilize with the ATR-1-ACE2 262 complex causing AT-1,7 generation leading to vasodilation and diminished inflammation [41]. These 263 effects may be more important than ACE-2 inhibition/viral entry inhibition. 264 In sum, animal studies have shown potential for benefit with ACEi/ARB in viral pneumonias and 265 inconsistent data suggesting potentially adverse increased ACE-2 expression. 266 Retrospective/observational clinical trials 267 A Chinese retrospective study compared mortality in hypertensive hospitalized COVID-19 patients who 268 were taking ACEi/ARB or were not [1]. Unadjusted and adjusted mortality was lower with ACEi/ARB. 269 In another Chinese retrospective study in hypertensive hospitalized COVID-19 patients, progression to 270 severe disease/mortality was similar in those taking vs. not taking ACEi/ARB [2]. An observational 271 database of international hospitalized COVID-19 patients showed similar in-hospital mortality for 272 ACEi/ARB use [3]. A NYU database review found no association for ACEi/ARB use and COVID-19 or 273 severe COVID-19 [4]. An Italian case-control study found no association for ACEi/ARB use and 274 COVID-19 [5].

In another hospitalized COVID-19 patient cohort, adjusted death/ICU transfer occurred less frequently

with ACEi vs. non-ACEi use [6]. Danish national registry retrospective cohort and case-control studies

found no significant associations for mortality and composite mortality/severe COVID-19 in patients

taking vs. not taking ACEi/ARB [7]. An observational trial evaluating hydroxychloroquine/chloroquine

found baseline ACEi (but not ARB) use to be associated with decreased mortality [3]. A Cleveland Clinic

Health System retrospective cohort study reported no association for ACEi/ARB use and COVID-19 [8].

In a retrospective Stanford study of COVID-19 inpatients/outpatients, ACEi/ARB use was not associated

with higher hospitalization, ICU risk, or death; hospitalization was lower [9].

In sum, these retrospective studies showed no safety signals for ACEi or ARB in COVID-19 [10] and

- possible benefit in some, supporting RCTs.
- 285 Retrospective/observational clinical trials in influenza
- A query of UK's Clinical Practice Research Datalink showed lower influenza rates with ACEi/ARB use
- vs. non-use [42]. Influenza A relies on the ACE2 receptor for lung entry, like SARS-CoV-2.
- 288 Prospective clinical trials

278

279

280

- The BRACE CORONA trial compared discontinuation vs. continuation of ACEi/ARB already taken by
- 290 659 mild-moderate hospitalized COVID-19 patients in Brazil [11]. Median time from symptoms onset
- was 6 days. The trial found no differences in the primary outcome of days alive outside the hospital at day
- 30 (mean, 21.9 vs. 22.9 days). No significant differences in mortality and AEs were seen.
- A second similar discontinuation vs. continuation trial of ARB already taken by 152 hospitalized COVID-
- 19 patients was also published (REPLACE COVID) [12]. Median time from symptoms onset was 6.5-6.8
- 295 days. There was no difference in the study's primary outcome, a global rank score including time-to-
- death, mechanical ventilation time, renal replacement, vasopressor time, and MOF. Mortality (13 vs.
- 15%), ICU admission/mechanical ventilation (18 vs. 21%), and AEs (36 vs. 39%) did not differ.
- We are aware of five published ACEi/ACE in COVID-19 intervention trials (four inpatient, one
- 299 outpatient).
- 300 The first, from University of Kansas, was a single-arm open-label trial assessing the ARB losartan in
- hospitalized COVID-19 patients requiring oxygen [13]. Thirty active treatment patients vs. 30 post-hoc
- external controls using propensity scores were compared, with the primary outcome being AE incidence.
- AE incidence (80 vs. 97%) and AE rates were lower with losartan (2.2 vs. 3.3); Poisson regression
- adjusted AE incidence ratio remained lower with losartan (0.69; 95% CI: 0.49-0.97); elevated creatinine
- AEs occurred in 30 vs. 23%, and elevated AST in 33 vs. 63%. No significant differences were found for

306 death (1/30 vs. 3/30) or mechanical ventilation (2/17 vs. 5/17) (trends favored losartan); hospital and ICU LOS and days requiring oxygen or mechanical ventilation were similar. Study limitations included single-307 308 arm, nonrandomized, open-label design with external historical controls, and between-group imbalance. 309 34 of 347 screened patients were enrolled (10%). 310 The second, an open-label RCT compared the ARB telmisartan and SOC vs. SOC alone in two 311 hospitalized COVID-19 patients in Argentina up to 4 days post symptoms onset (earlier than our trial) 312 [14]. The primary outcome was CRP at days 5 and 8. In an interim analysis, 40 telmisartan/SOC vs. 38 313 SOC were compared. Mean CRP was significantly lower in telmisartan/SOC vs. SOC groups at days 5 314 (24.2 vs. 51.1 mg/L [p<0.05]) and 8 (9.0 vs. 41.6 mg/L [p<0.05]). Median time to discharge was shorter with telmisartan, 9 vs. 15 days (p=0.01) and 30-day mortality trend favored telmisartan (5.26 vs. 11.76%, 315 316 p=0.41); there were no differences for ICU admission, mechanical ventilation, and a composite of ICU 317 admission, mechanical ventilation, and death; fewer patients receiving telmisartan needed oxygen at day 318 15 (2/4 vs. 13/14, p<0.05). No telmisartan related AEs occurred and BP was similar. 82 of 185 screened 319 patients were enrolled (56% [higher than our trial]). 320 The third, an open-label RCT compared the ARB losartan and SOC vs. SOC alone in 31 SHARP (San 321 Diego) hospitalized patients with COVID-19 with mild hypoxia (requiring </= 3 L oxygen) [15]. The 322 primary measurement was a composite of mechanical ventilation/death. No significant primary or 323 secondary differences were found: the composite endpoint occurred in 1/16 vs. 1/15 losartan/SOC vs. 324 SOC patients; mortality occurred in 1/16 vs. 1/15 patients; mean LOS was 9 vs. 10 days; hypotension 325 occurred in 3/16 vs. 4/15. O2 requirements were similar. 326 The fourth, the first blinded placebo-controlled RCT, compared losartan to placebo in outpatients with 327 mild COVID-19 conducted by University of Minnesota [17]. Of 117 enrolled patients, hospitalization 328 (primary outcome) occurred in 3/58 (5.2%) vs. 1/59 (1.7%) of losartan vs. placebo patients – an insignificant absolute difference of -3.5% favoring placebo (95% CI -13.2, 4.8%; p=0.320). ICU 329 330 admissions and viral loads were similar; there were no deaths. The rate of NCOSS <5 at day 15 was 7/55 331 (12.7%) with losartan and 2/54 (3.6%) with placebo, with an adjusted OR (age and gender) of -1.4 (95%) CI -3.4, 0.2; p = 0.096), favoring placebo. AE rates were similar, 0.33 vs. 0.37, respectively; SAE rates 332 333 were similar. No significant AKI, hypotension, or hyperkalemia occurred. This RCT was terminated early 334 due to futility due low rates of events. 117 of 14,371 screened patients were enrolled (0.81%); 89.8% did 335 not meet inclusion/exclusion criteria. 336 The fifth, also by University of Minnesota, was the second randomized placebo-controlled RCT, 337 comparing losartan (N=101) and placebo (N=104) in hospitalized COVID-19 patients [18]. Losartan 338 dosing was 50 mg twice daily for 10 days (higher than in our study). The primary outcome, the PaO2/FiO2 ratio at 7 days was similar [difference -24.8 (95% CI, -55.6 to 6.1; p=0.12)]. There were no 339 340 differences in secondary outcomes including 90-day mortality (10.9 vs. 10.6%, respectively), LOS, 341 oxygen and mechanical ventilation requirement at 10 days, or NCOSS. More losartan vs. placebo patients 342 needed vasopressors (20 vs. 11%, p=0.08) and vasopressor-free days were lower with losartan (8.7 vs. 343 9.4, p=0.04); our study found numerically higher hypotension AE/SAE rates analogously. Overall AE and 344 SAE rates were numerically higher with losartan (not significant); AKIs were more common with losartan (19.4 vs. 8.8%, p=0.04). This trial's design and applicability was most like ours, including low 345 346 enrollment:screening (5%). Notable differences include larger N, higher dosing, and lower mortality; 347 similarities include lack of efficacy findings accompanied by numerically higher safety signals with 348 losartan. 349 In sum, the ACEi/ARB continuation: discontinuation trials and small unblinded treatment trials in 350 hospitalized COVID-19 patients showed equivalent or improved outcome. In contrast, both blinded RCTs 351 showed lack of efficacy and adverse safety signals [17-18]. 352 Meta-analyses 353 A recent ACEi/ARB COVID-19 continuation: discontinuation meta-analysis (52 studies - 101,949 354 patients, 26,545 ACEi/ARB) found lower adjusted mortality and SAE rates with ACEi/ARB use [16]. 355 Two pooled analyses of ACEi/ARB in COVID-19 are currently being completed and results should be 356 forthcoming: (1) an IPD-based analysis of North American trials in hospitalized COVID-19 patients; (2) a larger aggregate data-based international meta-analysis by the International Society of Hypertension of 357 358 outpatient and hospitalized COVID-19 patients [43]. COVID MED data are included in both. 359 *Guidelines, professional societies, and reviews* 360 NIH guidelines, professional societies, and reviews recommend that ACEi/ARB, if already taken, should 361 be continued but not started anew outside RCTs [10, 29-30, 44-49]. 362 Study strengths and limitations 363 The strengths of our study include its design (randomized, controlled, blinded), minimal primary outcome measurements missingness, and baseline balance. Limitations include small N, early termination, 364 365 inclusion of lopinavir/ritonavir in post-hoc combined control comparisons, and low enrollment rate 366 making conclusions relevant to a small proportion of hospitalized COVID-19 patients.

Conclusions

369

370

371

372

373

374

375

376377

378

379

380

381

382

383

384

385

386387388

Our blinded and controlled RCT comparing losartan and control in hospitalized COVID-19 patients found no significant efficacy effect (NCOSS or mortality) which is not surprising given its small size, yet it found potential safety signals. We speculate that class adverse effects of ACEi/ARB may overcome theorized SARS-CoV-2-ACE-2 binding inhibition and other potential benefits making the overall benefit to risk ratio for these medications in COVID-19 null or negative. Given that results from our blinded RCT simulate those of the other two larger blinded RCTs to date, in effect a small third 'negative' RCT, unless forthcoming pooled analyses find conflicting results, ARBs should not be started de novo to treat COVID-19 outside of clinical trials. Acknowledgements We thank our study patients for participating in this RCT during the difficult times of the COVID-19 pandemic. We thank Jessica Kumar, MD, and Elizabeth Dufort, MD, and colleagues at New York State Department of Health, Albany, NY, for assistance with nasopharyngeal PCR processing and study drug supply. **Funding** This work was supported by a Bassett Research Institute ED Thomas Grant and salary support from the Bassett Research Institute and Bassett Medical Center's Department of Internal Medicine.

REFERENCES

- 390 1. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of Inpatient Use of Angiotensin
- Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients
- With Hypertension Hospitalized with COVID-19. Circulation Research 2020;**126**:1671–1681.
- 2. Li J, Wang X, Chen J, Zhang H, Deng D. Association of Renin-Angiotensin System Inhibitors With
- Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019
- 395 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol* 2020;**5**(**7**):825-830.
- 396 3. Mehra MR, Desai SS, Kuy SR, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and
- 397 Mortality in Covid-19. *N Engl J Med* 2020;**382**:e102.
- 398 4. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-Angiotensin-
- 399 Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020;**382**:2441-2448.
- 400 5. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System
- 401 Blockers and the Risk of Covid-19. *N Engl J Med* 2020;**382**:2431-2440.
- 402 6. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O' G, Pickles A, et al. Angiotensin-converting
- 403 enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19
- infection in a multi-site UK acute hospital trust. Eur J Heart Fail 2020;**22**(**6**):967-974.
- 405 7. Fosbol EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of
- Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19
- 407 Diagnosis and Mortality. *JAMA* 2020;**324**(2):168-177.
- 8. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of Use of
- 409 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing
- 410 Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;5(9):1020-1026.
- 411 9. Rubin SJS, Falkson SR, Degner NR, Blish CA. Safety of ACE-I and ARB medications in COVID-19:
- A retrospective cohort study of inpatients and outpatients in California. *J Clin Transl Sci* 2020; doi:
- 413 10.1017/cts.2020.489.
- 414 10. Jarcho JA, Ingelfinger JR, Hamel MB, D'Agostino Sr RB, Harrington DP. Inhibitors of the Renin-
- Angiotensin–Aldosterone System and Covid-19. *N Engl J Med* 2020;**382**(25):2462-2464.
- 416 11. Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, dos Santos TM, Mazzaet L,
- 417 al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and
- 418 Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With
- 419 COVID-19A Randomized Clinical Trial. *JAMA* 2021;**325**(3):254-264.
- 420 12. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medinaet C, al. Continuation versus
- discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a
- prospective, randomised, open-label trial. *Lancet Respir Med* 2021;**9**(3):275-284.

- 423 13. Bengtson CD, Montgomery RN, Nazir U, Satterwhite L, Kim MD, Bah NC, et al. An Open Label
- 424 Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. F Front
- 425 *Med (Lausanne)* 2021; doi: 10.3389/fmed.2021.630209.
- 426 14. Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for
- 427 treatment of Covid-19 patients: An open multicenter randomized clinical trial.
- 428 *EClinicalMedicine* 2021; doi: 10.1016/j.eclinm.2021.100962.
- 15. Geriak M, Haddad F, Kullar R, Greenwood KL, Habib M, Habib C, et al. Randomized Prospective
- Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized
- COVID-19 Patients with Mild Hypoxemia. *Infect Dis Ther* 2021;**10**(**3**):1323-1330.
- 432 16. Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association Between Renin-
- Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19A
- 434 Systematic Review and Meta-analysis. *JAMA Netw Open* 2021;**4**(3):e213594.
- 435 17. Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, et al. A multi-
- center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.
- 437 *EClinicalMedicine* 2021; doi: 10.1016/j.eclinm.2021.100957.
- 18. Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Black LP, et al. A multi-center phase II
- randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine.
- 440 37. 100957. 10.1016/j.eclinm.2021.100957.
- 441 19. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of
- 442 Hydroxychloroquine in Hospitalized Patients with Covid-19. The RECOVERY Collaborative Group.
- *N Engl J Med* 2020;**383(21)**:2030-2040.
- 20. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults
- 445 Hospitalized with Severe Covid-19. *N Engl J Med* 2020;**382(19)**:1787-1799.
- 446 21. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from
- Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol* 2020;
- doi: 10.1128/JVI.00127-20. Print 2020 Mar 17.
- 22. Letko M and Munster V, 2020. Functional assessment of cell entry and receptor usage for lineage B
- β-coronaviruses, including 2019-nCoV. Nat Microbiol 2020; https://doi.org/10.1038/s41564-020-
- 451 0688-y.
- 452 23. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated
- with a new coronavirus of probable bat origin. *Nature* 2020;**579**:270–273 (2020).
- 454 24. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019
- novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;**395(10224)**:565-
- 456 574.

- 457 25. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2
- 458 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
- 459 Inhibitor. Cell 2020;181(2):271-280.
- 26. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guanet B, et al. A crucial role of angiotensin converting
- enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Letter. *Nat Med* 2005;**11**:875–879.
- 462 27. Yan Y, Liu Q, Li N, Du JC, Li X, Li C, et al. Angiotensin II receptor blocker as a novel therapy in
- acute lung injury induced by avian influenza A H5N1 virus infection in mouse. LETTER TO THE
- 464 EDITOR. Sci China Life Sci 2015:**58**(2):208-11.
- 465 28. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased
- risk for COVID-19 infection? *Lancet Respir Med* 2020; doi: 10.1016/S2213-2600(20)30116-8.
- 29. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-
- 468 Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020;
- **382**:1653-1659.
- 470 30. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re:
- 471 Using RAAS Antagonists in COVID-19. *J Card Fail* 2020; doi: 10.1016/j.cardfail.2020.04.013.
- 472 31. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of
- 473 Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac
- Angiotensin-Converting Enzyme 2. *Circulation* 2005;**111(20)**:2605-10.
- 475 32. Zheng Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol
- 476 2020;**17**(**5**):259-260.
- 477 33. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril Attenuates
- Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction
- in Myocardial Infarcted Rat. *Hypertension* 2006;**48(4)**:572-8.
- 480 34. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of
- 481 Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II
- 482 Receptors. *Hypertension* 2004;**43**(**5**):970-6.
- 483 35. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the Renal
- Vasculature: Amplification by Angiotensin II Type 1 Receptor Blockade Using Telmisartan. Am J
- 485 *Physiol Renal Physiol* 2009;**296(2)**:F398-405.
- 486 36. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, et al. Myocardial infarction
- 487 increases ACE2 expression in rat and humans. Eur Heart J 2005;**26(4)**:369-75.
- 488 37. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-
- angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial
- infarction: implications for future therapeutic directions. *Clin Sci (Lond)* 2012;**123(11)**:649-58.

- 491 38. Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Converting enzyme 2
- activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is
- associated with atrial fibrillation and more advanced left atrial structural remodeling. Europace
- 494 2017;**19(8**):1280-1287.
- 495 39. Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated Plasma Angiotensin
- Converting Enzyme 2 Activity Is an Independent Predictor of Major Adverse Cardiac Events in
- Patients With Obstructive Coronary Artery Disease. PLoS One 2018; doi:
- 498 10.1371/journal.pone.0198144.
- 499 40. Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-
- converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II
- receptor blocker. *Am J Hypertens* 2015;**28**(1):15-21.
- 41. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological
- relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
- 504 *Pharmacol Res* 2017;**125(Pt A)**:21-38.
- 505 42. Chung S-C, Providencia R, Sofat R. Association between Angiotensin Blockade and Incidence of
- Influenza in the United Kingdom. *N Engl J Med* 2020;**383**(**4**):397-400.
- 43. Gnanenthiran SR, Borghi C, Burger D, Charchar F, Poulter NR, Schlaich MP, et al. Prospective meta-
- analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with
- 509 COVID-19: an initiative of the International Society of Hypertension. BMJ Open 2021; doi:
- 510 10.1136/bmjopen-2020-043625.
- 511 44. NIH COVID-19 Treatment Guidelines. (Updated August 4, 2021. Accessed 21 September 2021.)
- 512 Available from https://www.covid19treatmentguidelines.nih.gov/therapies/concomitant-medications/.
- 513 45. de Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and
- Angiotensin Receptor Blockers. European Society of Cardiology. (13 March 2021; Accessed 1
- October 2021.) Available from https://www.escardio.org/Councils/Council-on-Hypertension-
- 516 (CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
- 46. Patel AB and Verma A. Nasal ACE2 Levels and COVID-19 in Children. JAMA 2020;323(23):2386–
- 518 2387.
- 519 47. Patel AB and Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin
- 520 Receptor Blockers: What Is the Evidence? *JAMA* 2020;**323**(18):1769–1770.
- 521 48. Lubel J and Garg M. Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19. N Engl J Med
- 522 2020;**382(24)**:e92.
- 523 49. Curfman G. Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19.
- 524 *JAMA* 2020;**324(2)**:177-178.

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

Figure legends Figure 1. NCOSS over time +/- SEM. Figure on left compares losartan and combined control (lopinavir/ritonavir and placebo). Figure on right compares losartan and placebo only control. Comparisons of the slopes of the change for NCOSS, our primary outcome, revealed: losartan vs. combined control (p=0.4), losartan vs. placebo only control (p=0.05) (trend favoring placebo), combined control vs. placebo only control (p=0.267). Table legends Table 1. Baseline parameters/demographics. Losartan is compared with combined control (lopinavir/ritonavir and placebo) and placebo only control. Statistically significant and 'trend' comparisons are in bold. **Table 2.** Efficacy. Losartan is compared with combined control (lopinavir/ritonavir and placebo) and placebo only control. Statistically significant and 'trend' comparisons are in bold. Comparison of NCOSS slope of the change was the study's primary efficacy outcome measurement. Table 3. Safety. AE and SAE rates including relatedness. Losartan is compared with combined control (lopinavir/ritonavir and placebo) and placebo only control. Statistically significant and 'trend' comparisons are in bold. Comparison of SAE rate was the study's primary safety outcome measurement.

	Treatment	Combined control	р	95% CI	Placebo only control	р	95% CI
	Losartan	Lopinavir/ritonavir and placebo			Placebo		
N	9	5	NA	NA	3	NA	NA
Age (mean)	63.7	61.8	0.8	-17.0153 to 13.2153	56.3	0.4	-27.4633 to 12.6633
Ma le (%)	66.7	60.0	0.9	-0.80986 to 0.94319	66.7	NA	NA
Enrollments pring 2020	11.1	60	0.1	-1.0732 to 0.0955	33.3	0.4	-0.7557 to 0.3112
Enrollment fall 2020 - winter 2021	77.8	20	0.2	-0.2486 to 1.4042	33.3	0.4	-0.6224 to 1.5113
Enrollments pring 2021	11.1	20	0.7	-0.50209 to 0.32431	33.3	0.4	-0.7557 to 0.3112
Caucasian ethnicity (%)	100	100	NA	NA	100	NA	NA
NCOSS (mean)	3.6	4.0	0.5	-0.7192 to 1.5192	3.7	0.9	-1.2961 to 1.4961
Symptoms duration, days (mean)	9.3	7.4	0.3	-6.0157 to 2.315	6.7	0.3	-7.9688 to 2.8688
Comorbidites (targeted) rate (mean)	1.0	2.6	0.02	0.3255 to 2.8745	2.7	0.046	0.0392 to 3.3608
Immunoco mpro mised (%)	22.2	60	0.3	-1.0311 to 0.2755	66.7	0.2	-1.1988 to 0.3099
Chronic heart disease (%)	22.2	80	0.1	-1.2935 to 0.1379	66.7	0.2	-1.1988 to 0.3099
Chronic lung disease (%)	33.3	60	0.5	-0.9823 to 0.449	66.7	0.5	-1.1768 to 0.5101
Chronic kidney disease (%)	0	0	NA	NA	0	NA	NA
Chronic liver disease (%)	0	0	NA	NA	0	NA	NA
Diabetes (%)	22.2	25	0.9	-0.48384 to 0.52828	33.3	0.7	-0.7644 to 0.5422
Extreme obesity (%)	0	50	0.03	-0.962 to -0.038	50	0.03	-0.962 to -0.038
Charlson Score (mean)	2.5	4.5	0.08	-0.3196 to 4.3196	3.7	0.3	-1.1366 to 3.5366
qSOFA (mean)	0.33	0.6	0.4	-0.3585 to 0.8985	0.3	1	-0.7680 to 0.7680
BMI (mean)	31.0	31.8	0.4	-4.2764 to 9.2764	35.1	0.2	-2.3076 to 10.5076
Creatinine (mean)	0.7	0.9	0.4	-0.2508 to 0.5708	0.7	0.9	-0.2127 to 0.2327
Chest x-ray o pacities (%)	88.9	100	0.9	-1.1646 to 0.9423	100	0.9	-1.3621 to 1.1399
Pneu monia severity index (PSI) (mean)	54.9	59.3	0.5	-41.3071 to 50.1071	60	0.8	-40.4537 to 21.2537
Treatment days (mean)	9.6	13.3	0.3	-3.5545 to 10.8545	13	0.4	-5.1086 to 11.9086
Treatment with corticosteroids (%)	88.9	40	0.3	-0.7949 to 0.2172	60	0.7	-0.9706 to 1.415

Table 1.

	Treatment	Combined control	р	95% CI	Place bo only control	р	95% CI
	Losartan	Lopinavir/ritonavir and placebo			Place bo		
NC OSS s lope of the change	0.0037	0.0209	0.4		0.0527	0.05	
NC OSS change day 60		1.8	0.6	-2.8175 to 5.0175	3.3	0.2	-1.6690 to 6.8690
Mortality, 60 days (%)	44.4	20.0	0.9	-0.67123 to 0.76012	0	0.2	-0.3099 to 1.1988
First negative PCR, days (mean)	6.5	10.5	0.7	-12.3243 to 16.3243	3	NA	NA
Hospital LOS, days (mean)	16.4	7.0	0.2	- 25. 29 22 to 6. 49 22	6.3	0.3	- 28.8728 to 8.6728
Mechanical ventilation, days (mean)	8.5	0	NA	NA	0	NA	NA

Table 2.

	Losartan				Control (place bo or lopinavir/ritonavir)					р	95% CI		Control (placebo)						
	Total	De finitely	P ro bably	Possibly	Not	Total	Definitely	Probably	Possibly	Not			Total	Definitely	Probably	Possibly	Not	р	95% CI
AEs/subject (mean)	3.9	0	0	1.0	2.9	1.0	0	0	1.0	0	0.3	-8.3414 to 2.5414	0	0	0	0	0	NA	NA
SAEs/subject (mean)		0	0	0.4	1.6	0.60	0	0	0.6	0	0.3	-4.3144 to 1.5144	0	0	0	0	0	NA	NA
AKI AEs/subject (mean)	0.22	0	0	0.11	0.11	0.20	0	0	0.2	0	0.95	-0.7560 to 0.7160	0	0	0	0	0	NA	NA
AKI SAEe/subject (mean)	0.11	0	0	0.00	0.11	0.20	0	0	0.2	0	0.5	-0.5160 to 0.9560	0	0	0	0	0	NA	NA
Hypotension AEs/subject (mean)	0.33	0	0	0.22	0.11	0	0	0	0	0	NA	NA	0	0	0	0	0	NA	NA
Hypotension SAEs/subject (mean)	0.22	0	0	0.11	0.11	0	0	0	0	0	NA	NA	0	0	0	0	0	NA	NA
Hyperkalemia AEs/subject (mean)	0.11	0	0	0.11	0	0	0	0	0	0	NA	NA	0	0	0	0	0	NA	NA
Hyperkalemia SAEs/subject (mean)	0.00	0	0	0	0	0	0	0	0	0	NA	NA	0	0	0	0	0	NA	NA
Respiratory failure/COVID-19 PNA AEs rate (mean)	0.67	0	0	0.33	0.33	0.20	0	0	0.2	0	0.2	-1.2420 to 0.3020	0	0	0	0	0	NA	NA
Respiratory failure/COVID-19 PNA SAEs rate (mean)	0.67	0	0	0.33	0.33	0.20	0	0	0.2	0	0.2	-1.2420 to 0.3020	0	0	0	0	0	NA	NA

Table 3.




Figure 1